Endologix gains FDA nod for PowerFit Aortic Extensions.
M2 PHARMA-July 30, 2010-Endologix gains FDA nod for PowerFit Aortic Extensions(C)2010 M2 COMMUNICATIONS
30 July 2010 - Endologix Inc (NASDAQ: ELGX), a US-based developer of minimally invasive treatments for aortic disorders, said on Thursday that the US Food and Drug Administration (FDA) has approved its new PowerFit Aortic Extensions.
The PowerFit extensions are designed to provide physicians with enhanced visibility under fluoroscopy to facilitate precise device placement during completion of the Anatomical Fixation endovascular repair of abdominal aortic aneurysm (AAA), the company said. In addition, PowerFit's independent stent design and 24 circumferential contact points were shown in anatomical simulation studies to aid in proximal conformability and sealing.
PowerFit is designed for use with Endologix's existing products, including Powerlink main body bifurcated stent grafts and the IntuiTrak Endovascular System. It will be available in a range of sizes indicated to treat aortic necks ranging from 18 to 32 millimetres in diameter. The company said that in addition, the PowerFit product line will be available with longer stent lengths of up to 120 millimetres, to expand the treatment options for physicians and their patients.
PowerFit will initially be launched through a limited market release during the third quarter of 2010, followed by a full US market release during the fourth quarter of 2010, Endologix said.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 30, 2010|
|Previous Article:||Brokers review AstraZeneca after Q2 2010 report.|
|Next Article:||UCB out-licenses six products to Actient.|